Want to see SE:IVACC full AI Analyst Report?
IVACC Stock Chart & Stats
kr0.92
-kr0.06(-5.24%)
At close: 4:00 PM EST
kr0.92
-kr0.06(-5.24%)
Day’s Range― - ―
52-Week Rangekr0.57 - kr1.46
Previous CloseN/A
Volume791.15K
Average Volume (3M)373.34K
Market Cap
kr432.83M
Enterprise Valuekr135.56
Total Cash (Recent Filing)kr145.63M
Total Debt (Recent Filing)kr357.00K
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Aug 20, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume453,808
30 Day Avg. Volume373,337
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.22
Revenue Forecast (FY)kr16.00M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable EquityA very low debt profile and SEK/EUR-equivalent equity of 253.2M provide durable financial flexibility. Over a 2–6 month horizon this reduces refinancing and interest risks, sustains R&D and commercialization runway, and supports negotiations with partners despite ongoing losses.
Commercialized Core Product (Strangvac)Owning and commercializing Strangvac establishes a real revenue-generating asset with regulatory progress and partner distribution. This creates structural market access in equine health, recurring channel-driven sales, and a foundation for incremental geographic rollouts over the medium term.
Improving Free Cash Flow TrendA ~+48% improvement in free cash flow signals operational progress or tighter spending control. While still negative, the trend reduces near-term external funding needs, extends runway, and indicates management is beginning to narrow cash outflows versus prior periods.
Bears Say
Heavy Cash BurnSustained large negative operating and free cash flow means the business is not self-funding. Over a 2–6 month horizon this creates an ongoing need for external capital, raising dilution or financing risk and constraining investments in commercialization and R&D.
Negative Gross Profit And Extreme LossesNegative gross profit and outsized operating losses point to weak unit economics or very high fixed costs. Without gross margin reversal, scaling sales will not translate into profits; this undermines sustainable margins and long-term reinvestment capacity.
Modest, Recently Declining Revenue And Concentration RiskModest top-line scale with a recent YoY decline and heavy reliance on a single commercial vaccine creates concentration and execution risk. Any partner or adoption setback can materially hit revenue and delay margin recovery across the medium term.
Intervacc AB News
IVACC FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was kr0.57 and its highest was kr1.46 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is kr432.83M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Aug 20, 2026 which is in 24 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on May 13, 2026. The company reported -kr0.06 earnings per share for the quarter, the consensus estimate of -kr0.06 by kr0.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is -0.05.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -kr0.06 in its last earnings report, expectations of -kr0.06. Following the earnings report the stock price went down -14.82%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in SE:IVACC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―